Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

  • Cancer
  • Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Active, not recruiting

This trial runs in
  • Alessandria
  • Avellino
  • Aviano
  • Bari
  • Barletta
  • Bergamo
  • Bologna
  • Cagliari
  • Campania
  • Caserta
  • Catania
  • Firenze
  • Lazio
  • Lecce
  • Milano
  • Modena
  • Napoli
  • Nuoro
  • Padova
  • Palermo
  • Pavia
  • Perugia
  • Pescara
  • Pisa
  • Prato
  • Reggio Calabria
  • Reggio Emilia
  • Roma
  • San Giovanni Rotondo
  • Siena
  • Terni
  • Torino
  • Torrette
  • Treviso
  • Tricase
  • Udine
  • Varese
  • Verona
Trial Identifier:

NCT04034056 ML41215

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      To evaluate the effectiveness and safety of obinutuzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.

      Hoffmann-La Roche Sponsor
      NCT04034056,ML41215 Trial Identifier
      Obinutuzumab Treatments
      Follicular Lymphoma Condition
      Official Title

      A Non-Interventional, Retrospective And Prospective, Multicenter, Single Arm Study Evaluating The Effectiveness And Safety Of Obinutuzumab In Patients With Previously Untreated Advanced Follicular Lymphoma

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Signed Informed consent according to local regulations, after performing at least 2 cycles of induction treatment with Obinutuzumab and chemotherapy, within 1 year from beginning of treatment
      Exclusion Criteria
      • Any contraindications to Obinutuzumab therapy according to local label for specific indication;
      • Concomitant participation in an interventional clinical study;
      • Participants not receiving treatment for untreated follicular lymphoma with Obinutuzumab according to standard of care and in line with local labeling.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now